RxDoctor Payments Data

James Bennett, MD

Rheumatology · Helena, MTNPI 1588920896

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $362 of the $462 with a category attached, or 78.4%. 9 manufacturers reported payments, led by Genentech USA, Inc. at 34.3% of the total. Reporting peaked in 2019 at $321 and has fallen 76.3% since, to $76 in 2024.

$462in general payments, 2019–2025

Across 22 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$158
  • Sanofi$99
  • AbbVie$46
  • Amgen$38
  • GSK$37
  • Daiichi Sankyo Inc.$30
  • plus $54 from 3 others

What the payments were for

  • Food & beverage$36278%
  • Education$10022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech USA, Inc.8$158
Sanofi1$99
AbbVie3$46
Amgen(2 entities)3$38
GSK1$37
Daiichi Sankyo Inc.2$30
AstraZeneca2$26
Pfizer1$19
Organon1$9

How this compares

Too few rheumatology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$75,634
Medicare patients
284
Services billed
701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab52$340,861
Enbrel SureclickEtanercept29$221,684
HumiraAdalimumab20$205,756
Cimzia (2 Pack)Certolizumab Pegol30$166,481
Humira(Cf)Adalimumab25$165,973
Xeljanz XrTofacitinib Citrate28$156,967
RinvoqUpadacitinib11$97,070
EnbrelEtanercept13$93,044
XeljanzTofacitinib Citrate12$64,986
Mycophenolic AcidMycophenolate Sodium18$13,545
Hydroxychloroquine Sulfate286$11,245
MethotrexateMethotrexate Sodium318$9,182
Diclofenac Sodium17$8,403
EliquisApixaban11$6,253
Mycophenolate Mofetil60$5,582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira, Humira(Cf), Rinvoq$46$468,79856 claims
AmgenEnbrel$38$93,04413 claims
PfizerXeljanz, Eliquis$19$71,23923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →